GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pet Pharm Biotech Co Ltd (ROCO:7762) » Definitions » Net Income From Continuing Operations

Pet Pharm Biotech Co (ROCO:7762) Net Income From Continuing Operations : NT$12.4 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Pet Pharm Biotech Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Pet Pharm Biotech Co's net income from continuing operations for the six months ended in Dec. 2024 was NT$9.1 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was NT$12.4 Mil.

Pet Pharm Biotech Co Net Income From Continuing Operations Historical Data

The historical data trend for Pet Pharm Biotech Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pet Pharm Biotech Co Net Income From Continuing Operations Chart

Pet Pharm Biotech Co Annual Data
Trend Dec22 Dec23 Dec24
Net Income From Continuing Operations
-3.81 9.15 12.42

Pet Pharm Biotech Co Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24
Net Income From Continuing Operations - 4.87 4.28 3.37 9.05

Pet Pharm Biotech Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$12.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pet Pharm Biotech Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pet Pharm Biotech Co Ltd (ROCO:7762) » Definitions » Net Income From Continuing Operations
Comparable Companies
ROCO:6130 ROCO:4102 LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN GILD PFE XPAR:SAN BMY TSE:4519 LSE:GSK TSE:4568 SHSE:600276 XTER:BAYN
Traded in Other Exchanges
N/A
Address
143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051
Website
https://www.petpharmbio.com
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.

Pet Pharm Biotech Co Headlines

No Headlines